AcquisitionOther
Longevity Health Holdings, Inc. acquired Carmell Therapeutics
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Longevity Health Holdings, Inc. -> Carmell Therapeutics · $59 million
The Carmell technology platform is based on plasma-derived growth factors, whereas Elevai is based on exosomes derived from hUM stem cells.
Open source record (SEC) ↗